Subject(s)
Humans , Periodicals as Topic/trends , Editorial Policies , Impact Factor , Periodical , Internet , Mycology/trendsABSTRACT
Identification of unusual fungal isolates is a major challenge for the clinical laboratory. This report describes the isolation of Candida africana from a patient with vaginitis. This is a doubtful species which possibly represents atypical strains of Candida albicans. Candida africana can be separated morphologically and physiologically from C. albicans but not genetically. The analysis of 26S rRNA gene showed near 100% homology between C. africana and C. albicans.
Subject(s)
Candida/isolation & purification , Vaginitis/microbiology , Adult , Candida/classification , Candida/genetics , Candida albicans/genetics , Candidiasis/diagnosis , Candidiasis/microbiology , DNA, Ribosomal/analysis , DNA, Ribosomal/genetics , Female , Humans , RNA, Ribosomal/geneticsABSTRACT
We have compared two diagnostic systems, API-ID32C (bioMerieux) and VITEK-2ID-YST (bioMerieux), in their ability to diagnose 50 clinical isolates of Candida dubliniensis. API identified 48 isolates and VITEK-2 identified 33 of the 50 isolates. Lactic acid assimilation showed highly dispersed results with API, being of special importance, since this test is one of the four that makes it possible to differentiate C. dubliniensis from C. albicans. The detection of one enzyme, Phosphate-4MU, was always positive with VITEK-2 when it should have been negative. Overall, API ID 32C obtained better results than VITEK-2. However, the latter is simpler to use and has a greater database.
Subject(s)
Candida/classification , Mycological Typing Techniques/methods , Automation , Candidiasis/microbiology , Humans , Reproducibility of Results , Sensitivity and Specificity , Species SpecificityABSTRACT
The aim of this study was to determine the prevalence of primary resistance to 5-fluorocytosine (5FC) among clinical isolates of yeasts in Spain where this drug is not currently available for therapy. We have tested the in vitro activity of 5FC against 1,021 recent yeast clinical isolates, including 522 Candida albicans, 140 Candida parapsilosis, 68 Candida glabrata, 41 Candida dubliniensis, 50 Candida guilliermondii, 34 Candida tropicalis, 28 Candida krusei, 20 Candida famata, 11 Cryptococcus neoformans, 5 Cryptococcus albidus, 43 Rhodotorula spp., 24 Trichosporon spp., 5 Saccharomyces cerevisiae, 9 Pichia spp., and 21 isolates from other 11 yeast species. The MICs were determined by the ATB Fungus agar microdilution test (bioMerieux, France) and the following interpretive breakpoints were used: susceptible, > 4 microg/ml; intermediate, 8 to 16 microg/ml; resistant, > 32 microg/ml. 5FC was very active against Candida spp. and other medically important yeasts as 852 (83.4%) of the studied isolates were susceptible (MIC < 4 microg/ml). The species most susceptible to 5FC were C. dubliniensis (100%of isolates; MIC90, 0.25 microg/ml), C. famata (100% of isolates; MIC90, 0.25 microg/ml), C. guilliermondii (98%of isolates; MIC90, 0.25 microg/ml), C. glabrata (95.5% of isolates; MIC90, 0.25 microg/ml), and C. neoformans (90.9% of isolates; MIC90, 2 microg/ml). Primary resistance to 5FC was very uncommon, and a MIC > 32 microg/ml, indicator of in vitro resistance, was observed in 106 isolates (10.4%): 77 C. albicans (16.5% of isolates; MIC90, > 128 microg/ml), 9 C. parapsilosis (6.4% of isolates; MIC90, 8 microg/ml), 4 C. albidus (80% of isolates, MIC50, > 128 microg/ml), 3 C. glabrata (4.4% of isolates; MIC90, 0.25 microg/ml), 3 C. tropicalis (8.8% of isolates; MIC90, 4 microg/ml), 2 C. krusei (7.1% of isolates; MIC90, 8 microg/ml), 2 Rhodotorula spp. (4.6% of isolates, MIC90, 1 microg/ml), 8 Trichosporon spp. (33.3% of isolates; MIC90, 64 microg/ml), and 1 C. lipolytica (50% of isolates). Interestingly, most C. albicans (67 out of 77 isolates) resistant to 5FC were serotype B isolates.
